Published in Thromb Haemost on October 01, 2005
Platelets as cellular effectors of inflammation in vascular diseases. Circ Res (2013) 2.62
Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol (2009) 1.70
Regulatory effects of TLR2 on megakaryocytic cell function. Blood (2011) 1.53
Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res (2008) 1.52
Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol (2011) 1.26
Lipopolysaccharide is a direct agonist for platelet RNA splicing. J Immunol (2008) 1.24
Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. Circ Res (2012) 1.24
The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. J Thromb Haemost (2011) 1.15
Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res (2010) 1.04
Translational mini-review series on immunology of vascular disease: inflammation, infections and Toll-like receptors in cardiovascular disease. Clin Exp Immunol (2009) 0.96
Differential modulation of cytokine, chemokine and Toll like receptor expression in chickens infected with classical and variant infectious bursal disease virus. Vet Res (2011) 0.92
Lipopolysaccharide stimulates platelets through an IL-1β autocrine loop. J Immunol (2013) 0.91
The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes. Thromb Res (2009) 0.90
Platelets and infections - complex interactions with bacteria. Front Immunol (2015) 0.90
A central role for monocytes in Toll-like receptor-mediated activation of the vasculature. Immunology (2009) 0.89
The Inflammatory Role of Platelets via Their TLRs and Siglec Receptors. Front Immunol (2015) 0.88
Emerging evidence for platelets as immune and inflammatory effector cells. Front Immunol (2014) 0.85
Platelets as central mediators of systemic inflammatory responses. Thromb Res (2010) 0.84
The role of calpain-myosin 9-Rab7b pathway in mediating the expression of Toll-like receptor 4 in platelets: a novel mechanism involved in α-granules trafficking. PLoS One (2014) 0.83
Review of cellular and molecular pathways linking thrombosis and innate immune system during sepsis. J Res Med Sci (2010) 0.82
Aggregation and microparticle production through toll-like receptor 4 activation in platelets from recently menopausal women. J Cardiovasc Pharmacol (2009) 0.81
Brief Exercise Increases Peripheral Blood NK Cell Counts without Immediate Functional Changes, but Impairs their Responses to ex vivo Stimulation. Front Immunol (2013) 0.79
Expression and functionality of Toll-like receptor 3 in the megakaryocytic lineage. J Thromb Haemost (2015) 0.76
Platelet-borne complement proteins and their role in platelet-bacteria interactions. J Thromb Haemost (2016) 0.76
Role of platelet TLR4 expression in pathogensis of septic thrombocytopenia. World J Emerg Med (2011) 0.75
Hyaluronan Depolymerization by Megakaryocyte Hyaluronidase-2 Is Required for Thrombopoiesis. Am J Pathol (2016) 0.75
The thrombotic potential of oral pathogens. J Oral Microbiol (2009) 0.75
Intercellular Interactions as Regulators of NETosis. Front Immunol (2016) 0.75
Toll-Like Receptor Signalling Is Not Involved in Platelet Response to Streptococcus pneumoniae In Vitro or In Vivo. PLoS One (2016) 0.75
Platelets in neutrophil recruitment to sites of inflammation. Curr Opin Hematol (2017) 0.75
P-Selectin Targeted Dexamethasone-Loaded Lipid Nanoemulsions: A Novel Therapy to Reduce Vascular Inflammation. Mediators Inflamm (2016) 0.75
Human platelet interaction with E. coli O111 promotes tissue-factor-dependent procoagulant activity, involving Toll like receptor 4. PLoS One (2017) 0.75
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
A transgenic zebrafish model of neutrophilic inflammation. Blood (2006) 3.93
The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One (2010) 3.30
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 2.98
Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J Biol Chem (2004) 2.91
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation (2009) 2.84
A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci Transl Med (2014) 2.51
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J Immunol (2002) 2.24
[ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol (2011) 2.21
Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol (2003) 2.18
Pivotal Advance: Pharmacological manipulation of inflammation resolution during spontaneously resolving tissue neutrophilia in the zebrafish. J Leukoc Biol (2010) 2.08
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation (2013) 2.03
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol (2007) 2.01
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2010) 2.00
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke (2013) 1.99
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J (2011) 1.98
TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol (2011) 1.98
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2010) 1.96
Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J Immunol (2003) 1.88
Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin Res (2006) 1.86
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation (2012) 1.84
Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin. J Clin Invest (2008) 1.78
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet (2010) 1.77
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation (2012) 1.66
Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection. J Immunol (2002) 1.64
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation (2012) 1.62
Toll-like receptors in health and disease: complex questions remain. J Immunol (2003) 1.57
Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. Arthritis Rheum (2009) 1.55
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 1.51
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Rev Esp Cardiol (Engl Ed) (2015) 1.49
Hypoxia-inducible factor 2α regulates key neutrophil functions in humans, mice, and zebrafish. Blood (2013) 1.48
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv (2013) 1.46
Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value Health (2013) 1.45
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ (2012) 1.45
Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest (2011) 1.44
Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J Clin Invest (2005) 1.42
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets (2004) 1.42
Clopidogrel resistance. Catheter Cardiovasc Interv (2004) 1.42
Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol (2010) 1.41
Skin exposure to micro- and nano-particles can cause haemostasis in zebrafish larvae. Thromb Haemost (2010) 1.41
The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med (2002) 1.38
Acceleration of human neutrophil apoptosis by TRAIL. J Immunol (2003) 1.38
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J (2010) 1.34
Reactive oxygen species regulate neutrophil recruitment and survival in pneumococcal pneumonia. Am J Respir Crit Care Med (2008) 1.33
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2011) 1.33
Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection. FASEB J (2004) 1.33
Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol (2003) 1.32
The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis. Clin Infect Dis (2005) 1.30
Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses. FASEB J (2006) 1.30
Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs. Matrix Biol (2003) 1.27
Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia. J Immunol (2006) 1.27
The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol (2005) 1.26
Caspase-1-deficient mice have delayed neutrophil apoptosis and a prolonged inflammatory response to lipopolysaccharide-induced acute lung injury. J Immunol (2002) 1.25
Interleukin 18 receptor 1 gene polymorphisms are associated with asthma. Eur J Hum Genet (2008) 1.23
Phylogenetic and evolutionary analysis of the PLUNC gene family. Protein Sci (2004) 1.23
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
Pyocyanin production by Pseudomonas aeruginosa induces neutrophil apoptosis and impairs neutrophil-mediated host defenses in vivo. J Immunol (2005) 1.20
Human tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways. J Biol Chem (2007) 1.17
Update on lipids, inflammation and atherothrombosis. Thromb Haemost (2011) 1.16
Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J (2012) 1.16
Agonists of toll-like receptors 2 and 4 activate airway smooth muscle via mononuclear leukocytes. Am J Respir Crit Care Med (2005) 1.16
The role of TLRs in neutrophil activation. Curr Opin Pharmacol (2011) 1.15
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation (2011) 1.13
Toll-like receptor (TLR)2 and TLR4 agonists regulate CCR expression in human monocytic cells. J Immunol (2004) 1.12